Defective T‐cell response to COVID‐19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes

Justin Loke; Vinit Upasani; Charlotte Gaskell; Sonia Fox; Rachel Fletcher; Catherine Thomas; Louise Hopkins; Anita Kumari; Tina Tang; Emily Yafai; Rebecca Boucher; Victoria Homer; Arpad Toth; Y. L. Tracey Chan; Katie Randall; Tom Rider; Jenny O'nions; Victoria Drew; Arvind Pillai; Moez Dungarwalla; Duncan Murray; Anjum Khan; Farooq Wandroo; Sally Moore; Pramila Krishnamurthy; Ya‐wen Jessica Huang; Steve Knapper; Jenny Byrne; Rui Zhao; Charles Craddock; Helen Parry; Paul Moss; Simon J. Stanworth; David M. Lowe

doi:10.1111/bjh.18894

Defective T‐cell response to COVID‐19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes

Justin Loke
, Vinit Upasani
, Charlotte Gaskell
, Sonia Fox
, Rachel Fletcher
, Catherine Thomas
, Louise Hopkins
, Anita Kumari
, Tina Tang
, Emily Yafai
, Rebecca Boucher
, Victoria Homer
, Arpad Toth
, Y. L. Tracey Chan
, Katie Randall
, Tom Rider
, Jenny O'nions
, Victoria Drew
, Arvind Pillai
, Moez Dungarwalla

Duncan Murray, Anjum Khan, Farooq Wandroo, Sally Moore, Pramila Krishnamurthy, Ya‐wen Jessica Huang, Steve Knapper, Jenny Byrne, Rui Zhao, Charles Craddock, Helen Parry, Paul Moss, Simon J. Stanworth^*, David M. Lowe^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Limited data exist on COVID-19 vaccination efficacy in patients with acute myeloid leukemia and myelodysplasia with excess blasts (AML/MDS-EB2). We report results from a prospective study, PACE (Patients with AML and COVID-19 Epidemiology). 93 patients provided samples post-vaccine 2 or 3 (PV2, PV3). Antibodies against SARS-COV-2 spike antigen were detectable in all samples. Neutralization of the omicron variant was poorer than ancestral variants but improved PV3. In contrast, adequate T-cell reactivity to SARS-COV-2 spike protein was seen in only 16/47 (34%) patients PV2 and 23/52 (44%) PV3. Using regression models, disease response (not in CR/Cri), and increasing age predicted poor T cell response.

Original language	English
Pages (from-to)	498-503
Number of pages	6
Journal	British Journal of Haematology
Volume	202
Issue number	3
Early online date	12 Jun 2023
DOIs	https://doi.org/10.1111/bjh.18894
Publication status	Published - Aug 2023

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjh.18894Licence: None: All rights reserved

https://onlinelibrary.wiley.com/doi/10.1111/bjh.18894Licence: None: All rights reserved

Cite this

Loke, J., Upasani, V., Gaskell, C., Fox, S., Fletcher, R., Thomas, C., Hopkins, L., Kumari, A., Tang, T., Yafai, E., Boucher, R., Homer, V., Toth, A., Chan, Y. L. T., Randall, K., Rider, T., O'nions, J., Drew, V., Pillai, A., ... Lowe, D. M. (2023). Defective T‐cell response to COVID‐19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes. British Journal of Haematology, 202(3), 498-503. https://doi.org/10.1111/bjh.18894

@article{04ae2ac19f804f00a36ccd50ea57c51a,

title = "Defective T‐cell response to COVID‐19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes",

abstract = "Limited data exist on COVID-19 vaccination efficacy in patients with acute myeloid leukemia and myelodysplasia with excess blasts (AML/MDS-EB2). We report results from a prospective study, PACE (Patients with AML and COVID-19 Epidemiology). 93 patients provided samples post-vaccine 2 or 3 (PV2, PV3). Antibodies against SARS-COV-2 spike antigen were detectable in all samples. Neutralization of the omicron variant was poorer than ancestral variants but improved PV3. In contrast, adequate T-cell reactivity to SARS-COV-2 spike protein was seen in only 16/47 (34\%) patients PV2 and 23/52 (44\%) PV3. Using regression models, disease response (not in CR/Cri), and increasing age predicted poor T cell response.",

author = "Justin Loke and Vinit Upasani and Charlotte Gaskell and Sonia Fox and Rachel Fletcher and Catherine Thomas and Louise Hopkins and Anita Kumari and Tina Tang and Emily Yafai and Rebecca Boucher and Victoria Homer and Arpad Toth and Chan, \{Y. L. Tracey\} and Katie Randall and Tom Rider and Jenny O'nions and Victoria Drew and Arvind Pillai and Moez Dungarwalla and Duncan Murray and Anjum Khan and Farooq Wandroo and Sally Moore and Pramila Krishnamurthy and Huang, \{Ya‐wen Jessica\} and Steve Knapper and Jenny Byrne and Rui Zhao and Charles Craddock and Helen Parry and Paul Moss and Stanworth, \{Simon J.\} and Lowe, \{David M.\}",

note = "{\textcopyright} 2023 British Society for Haematology and John Wiley \& Sons Ltd.",

year = "2023",

month = aug,

doi = "10.1111/bjh.18894",

language = "English",

volume = "202",

pages = "498--503",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley",

number = "3",

}

Loke, J, Upasani, V, Gaskell, C, Fox, S, Fletcher, R, Thomas, C, Hopkins, L, Kumari, A, Tang, T, Yafai, E, Boucher, R , Homer, V, Toth, A, Chan, YLT, Randall, K, Rider, T, O'nions, J, Drew, V, Pillai, A, Dungarwalla, M, Murray, D, Khan, A, Wandroo, F, Moore, S, Krishnamurthy, P, Huang, YJ, Knapper, S, Byrne, J, Zhao, R, Craddock, C, Parry, H , Moss, P, Stanworth, SJ & Lowe, DM 2023, 'Defective T‐cell response to COVID‐19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes', British Journal of Haematology, vol. 202, no. 3, pp. 498-503. https://doi.org/10.1111/bjh.18894

TY - JOUR

T1 - Defective T‐cell response to COVID‐19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes

AU - Loke, Justin

AU - Upasani, Vinit

AU - Gaskell, Charlotte

AU - Fox, Sonia

AU - Fletcher, Rachel

AU - Thomas, Catherine

AU - Hopkins, Louise

AU - Kumari, Anita

AU - Tang, Tina

AU - Yafai, Emily

AU - Boucher, Rebecca

AU - Homer, Victoria

AU - Toth, Arpad

AU - Chan, Y. L. Tracey

AU - Randall, Katie

AU - Rider, Tom

AU - O'nions, Jenny

AU - Drew, Victoria

AU - Pillai, Arvind

AU - Dungarwalla, Moez

AU - Murray, Duncan

AU - Khan, Anjum

AU - Wandroo, Farooq

AU - Moore, Sally

AU - Krishnamurthy, Pramila

AU - Huang, Ya‐wen Jessica

AU - Knapper, Steve

AU - Byrne, Jenny

AU - Zhao, Rui

AU - Craddock, Charles

AU - Parry, Helen

AU - Moss, Paul

AU - Stanworth, Simon J.

AU - Lowe, David M.

PY - 2023/8

Y1 - 2023/8

N2 - Limited data exist on COVID-19 vaccination efficacy in patients with acute myeloid leukemia and myelodysplasia with excess blasts (AML/MDS-EB2). We report results from a prospective study, PACE (Patients with AML and COVID-19 Epidemiology). 93 patients provided samples post-vaccine 2 or 3 (PV2, PV3). Antibodies against SARS-COV-2 spike antigen were detectable in all samples. Neutralization of the omicron variant was poorer than ancestral variants but improved PV3. In contrast, adequate T-cell reactivity to SARS-COV-2 spike protein was seen in only 16/47 (34%) patients PV2 and 23/52 (44%) PV3. Using regression models, disease response (not in CR/Cri), and increasing age predicted poor T cell response.

AB - Limited data exist on COVID-19 vaccination efficacy in patients with acute myeloid leukemia and myelodysplasia with excess blasts (AML/MDS-EB2). We report results from a prospective study, PACE (Patients with AML and COVID-19 Epidemiology). 93 patients provided samples post-vaccine 2 or 3 (PV2, PV3). Antibodies against SARS-COV-2 spike antigen were detectable in all samples. Neutralization of the omicron variant was poorer than ancestral variants but improved PV3. In contrast, adequate T-cell reactivity to SARS-COV-2 spike protein was seen in only 16/47 (34%) patients PV2 and 23/52 (44%) PV3. Using regression models, disease response (not in CR/Cri), and increasing age predicted poor T cell response.

U2 - 10.1111/bjh.18894

DO - 10.1111/bjh.18894

M3 - Article

C2 - 37303189

SN - 0007-1048

VL - 202

SP - 498

EP - 503

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 3

ER -

Defective T‐cell response to COVID‐19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this